Literature DB >> 11730947

IL-7-enhanced T-cell response to myelin proteins in multiple sclerosis.

E Traggiai1, T Biagioli, E Rosati, C Ballerini, B Mazzanti, A Ben Nun, L Massacesi, M Vergelli.   

Abstract

In this study, we investigated the in vitro proliferative response of peripheral blood T lymphocytes from MS patients and controls to MBP and MOG either in the absence or in the presence of the conditioning factor IL-7. In the absence of IL-7, T-cell reactivity to MOG and MBP was similar in MS patients and controls even if an increased MBP response was found in a subgroup of patients with active disease. In the presence of IL-7, increased T-cell reactivity to MBP was observed in MS patients suggesting that their MBP-specific T cells are in a different functional state.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11730947     DOI: 10.1016/s0165-5728(01)00433-7

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  11 in total

1.  IL-7 induces clathrin-mediated endocytosis of CD127 and subsequent degradation by the proteasome in primary human CD8 T cells.

Authors:  Elliott M Faller; Feras M Ghazawi; Marko Cavar; Paul A MacPherson
Journal:  Immunol Cell Biol       Date:  2015-08-14       Impact factor: 5.126

Review 2.  Cytokine gene polymorphisms and human autoimmune disease in the era of genome-wide association studies.

Authors:  Koen Vandenbroeck
Journal:  J Interferon Cytokine Res       Date:  2011-12-22       Impact factor: 2.607

3.  Antisense modulation of IL7R splicing to control sIL7R expression in human CD4+ T cells.

Authors:  Gaddiel Galarza-Muñoz; Debbie Kennedy-Boone; Geraldine Schott; Shelton S Bradrick; Mariano A Garcia-Blanco
Journal:  RNA       Date:  2022-05-25       Impact factor: 5.636

Review 4.  Modulating T-cell homeostasis with IL-7: preclinical and clinical studies.

Authors:  C M Capitini; A A Chisti; C L Mackall
Journal:  J Intern Med       Date:  2009-08       Impact factor: 8.989

Review 5.  Gut commensalism, cytokines, and central nervous system demyelination.

Authors:  Kiel Telesford; Javier Ochoa-Repáraz; Lloyd H Kasper
Journal:  J Interferon Cytokine Res       Date:  2014-08       Impact factor: 2.607

6.  Cross-sectional and longitudinal analysis of myelin-reactive T cells in patients with multiple sclerosis.

Authors:  Jan D Lünemann; Sandra Rückert; Florian Kern; Uwe Wendling; Ruud van der Zee; Hans D Volk; Frauke Zipp
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

7.  Interleukin-12 (IL-12), but not IL-23, induces the expression of IL-7 in microglia and macrophages: implications for multiple sclerosis.

Authors:  Malabendu Jana; Susanta Mondal; Arundhati Jana; Kalipada Pahan
Journal:  Immunology       Date:  2014-04       Impact factor: 7.397

8.  Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia.

Authors:  Frederique Ponchel; Robert J Verburg; Sarah J Bingham; Andrew K Brown; John Moore; Andrew Protheroe; Kath Short; Catherine A Lawson; Ann W Morgan; Mark Quinn; Maya Buch; Sarah L Field; Sarah L Maltby; Aurelie Masurel; Susan H Douglas; Liz Straszynski; Ursula Fearon; Douglas J Veale; Poulam Patel; Dennis McGonagle; John Snowden; Alexander F Markham; David Ma; Jacob M van Laar; Helen A Papadaki; Paul Emery; John D Isaacs
Journal:  Arthritis Res Ther       Date:  2004-11-16       Impact factor: 5.156

9.  Genetic association of rs1520333 G/A polymorphism in the IL7 gene with multiple sclerosis susceptibility in Isfahan population.

Authors:  Reza Ghavimi; Meraj Pourhossein; Kamran Ghaedi; Fereshteh Alesahebfosoul; Mohamad Amin Honardoost; Mohamad Reza Maracy
Journal:  Adv Biomed Res       Date:  2014-11-29

10.  Activation of islet autoreactive naïve T cells in infants is influenced by homeostatic mechanisms and antigen-presenting capacity.

Authors:  Anne-Kristin Heninger; Paolo Monti; Carmen Wilhelm; Petra Schwaiger; Denise Kuehn; Anette-G Ziegler; Ezio Bonifacio
Journal:  Diabetes       Date:  2013-01-24       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.